BAB V. KESIMPULAN DAN SARAN
5.2. Saran
Perlu dilakukan penelitian lebih lanjut untuk mengetahui sensitifitas spesifisitas angiostatin urin sebagai prediktor dan prognosis pada tumor ovarium epitel jinak dan tumor ovarium epitel ganas.
DAFTAR PUSTAKA
1. Drenberg DC. Saunders OB. Wilbanks DG et al. Urinary Angiostatin levels are elevated in patients with Epithelial ovarian Cancer. Gynecologic Oncology. USA. 117:2010.117-124
2. Suhonen K. Prognostic Role of Cell Adhesion Factors and Angiogenesis in Epithelial Ovarian Cancer. Institute of Clinical Medicine University of Kuopio. Kuopio. 2007
3. Suh KS, Sang WP, Angelica C1, et al. Ovarian cancer biomarkers for molecular biosensors and translational medicine Expert Rev. Mol. Diagn. 10(8), 1069–1083. 2010.
4. Aziz MF, Andrijono, Saifuddinn AB. Buku acuan Nasional Onkologi Ginekologi. Yayasan Bina Pustaka Sarwono Prawirohardjo.
Departemen Ginekologi dan ginekologi fakultas kedokteran Indonesia. Edisi pertama. 2006; 469 – 527
5. Sahil MF. Penatalaksanaan Kanker Ovarium pada wanita usia muda dengan mempertahankan fungsi Reproduksi. Pidato Pengukuhan Guru Besar. Fakultas Kedokteran Sumatra Utara Departemen Obstetri dan Ginekologi. Universitas Sumatra Utara. Medan. 2007
6. Berek JS. Natarajan Sathima. Ovarian and Fallopian Tube Cancer. Berek & Novak’s Gynecology. Lippincott William and Wilkins. 14th edition.2007; 1457 – 1503
7. Danukusumo D. Akurasi pembedahan kanker ovarium, Tinjauan retrospektif di RS Cipto Mangunkusumo 1991. Simposium KeganasanOvarium, PTP POGI IX, 1991, Bandung.
8. Fadlan. Tinjauan Kasus Neoplasma Ovarium Ganas di Rumah Sakit Dr.Pirngadi Medan (1981–1990). Tesis pada Bagian Obstetri danGinekologi Fakultas Kedokteran USU, Medan, 1993.
9. Nurseta T. Kanker Ovarium. Panduan Penatalaksanaan kanker Ginekologi berdasarkan Evidence Base, Rasidi imam. Jakarta.EGC. 2007 :83-101
10. Veitonmaki niina. Angiostatic Mechanisms of Endogenous angiogenesis Inhibitor. Microbiology and tumor Biologi Center Karolinska Institutet, Stockholm, Sweden. 2003. ISBN 91-7349-555-7 11. Papathanassiu AE. Green JS. Grella DK. Sim BKL.
Angiostatin.entremed inc. Medical center drive. Rockville. MD 206406. USA. 2000
12. Zetter BR. Angiogenesis and tumor metastasis. Children’s Hospital. Harvard Medical School. Boston.Massachusetts. 1998: 49:407-27 13. Yokoyama Y. Dhanabal M. Griffioen AW. et all. Synergy between
Angiostatin and Endostatin: Inhibition of Ovarian Cancer Growth. Department of Pharmacology, Obstetrics and Gynecology, and Comprehensive Cancer Center. University of Minnesota. Minneapolis. Minnesota. Cancer Research 60. 2000; 2190-2196
14. Geiger JH and Cnudde SE. What the structure of angiostatin may tell us about its mechanism of action. Department of Chemistry and Department of Biochemistry. Michigan State University. USA. 2004. 23-34
15. Ray Bio. Human Angiostatin Elisa Kit Protocol. 2012.
16. Angiostatin Human Elisa Kit. Instruction for use. For the quantitative meansurement of human Angiostatin concentrations in serum, plasma, cell culture supernatant and urine.
17. Falcone DJ, Khan KMF, Layne T, Fernandes. Macrophage Formation of Angiostatin during Inflammation.a byproduct of the activation of plasminogen. Departments of Pathology and of cell Biology and Anatomi Cornell Medical College. New York. Vol. 273 no 47. 1998. 31480-3485
18. Sim B. Kim Lee, O’Reilly MS, et al. A Recombinant Human Angiostatin Protein Inhibints experimental Primary and Metastatic Cancer. Department of Cell Biology Harvard Medical School. Boston. Massachusetts. Cancer Res. 58. 1997; 329-1334.
19. Stragliotto CL, Strander H, Wikland EM, Linder MS. Low Levels of Endostatin in the Urine from Patients with Malignant Disease. Department of Clinical Chemistry and Blood Coagulation Karolinska Hospital. Stockholm. Sweden. 2002. 23: 222-227.
20. Eichhorn ME, Kleespies A, Angele MK, et al. Angiogenesis in cancer: molecular mechanisms, clinical impact. Department of Suegery Klinikum grosshadern University of Munich. Germany. 2007. 392:371-379.
21. Cao Yihai. Therapeutic potentials of angiostatin in the treadment of cancer. Laboratory of Angiogenesis Reasearch Microbiology and Tumor Biology Center Karolinska Institute Stockholm. Sweden. 1999; 84: 643-650.
22. Wahl ML, Moser TL and Pizzo SV. Angiostatin and Anti-angiogenic Therapy in Human Disease. Department of Pathology Duke University Medical Center Durham. Norh Carolina. 2004;73-82
23. Kubota Yoshiaki. Tumor Angiogenesis and Anti-angiogenic Therapy. Center for Integrated Medical Research. School of Medicine Keio University. Tokyo. Japan. 2011.
24. Dings RP, Yokoyama Y, Ramakrishnan S, et al. The Designed Angiostatic Peptide Angionex Synergistically Improves Chemotherapy and Antiangiogenesis Therapy with Angiostatin. Department of Biochemistry Molecular Biology and Biophysics University of Minnesota Health Sciences Center. Minnesota. 2003. 382-385.
25. Oklu R, Walker TG, Wicky S, Hesketh R. Angiogenesis and Current Antiangiogenic Strategies for the Treatment of Cancer. Department of Biochemistry University of Cambridge. United Kingdom. 2010;21:1791-1805.
26. Rosen Lee. Antiangiogenic Strategies and Agents in Clinical Trials. University of California Los Angeles School of Medicine. California. USA. 2000;5:20-27
27. Richard W, Castellino FJ, Chang Y, et al. Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. Department of Oncology Drug Discovery Bristol-Myers Squibb Pharmaceuticals Princeton. USA. The Faseb Journal vol. 12 n0:15. 1998;1731-1738
28. H. RN. Osteopontin sebagai penanda ganas tumor ovarium. Departemen Obstetri dan Ginekologi Fakultas Kedokteran Universitas Sumatra Utara.2001.1-41
29. Hacker NF, Benedet JL, Ngan HYS, Staging classifications and clinical practice guidelines of gynaecologic cancers. Internasional journal of Gynecology and obstetrics, 70. 2000.
30. Basile DP, Fredrich K, Weihrauch D, et al. Angiostatin and matrix metalloprotease expression following ischemic acute renal failure. Department of Physiology Luisiana State University Health Science Center. New Orleans. Louisiana. Am J Physiol Renal Physiol 286. 2004:F893-F902.
31. Albini A, Brigati C, Ventura A, et all. Angiostatin anti-angiogenesis requires IL-12: The innate immune system as a key target. Journal of Translation Medicine BioMed Central.
32. Gupta D, Lammersfeld AC, vashi GP, Braun PD. Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer. Cancer Treatment Centers of America. Midwestem. USAm. 2010,
33. Griscelli F, Li Hong, Bennaceur A, Soria J, et al. Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Institut National de la Sante et de la Recherche Medicale St.Louis. France. The National Academy of Sciences. 1998. Vol. 95. Pp. 6367-6372.
34. Tortora G, Melisi D and Ciardiello F. Angiogenesis: A Target for Cancer Therapy. Division of Medical Onkology, Department of Molecular and Clinical Endocrinology and Oncology. Universita di Napoli. Italu. 2004. 10. 11-24.
35. Folkman Judah. Kalluri Raghu. Tumor Angiogenesis. Agiogenesis Research. Cancer Biologi. 1985. Section 11. 162-194
36. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Ovarian Cancer, 2008. Available from:
37. Scappaticci FA, Smith R, Pathak A, et all. Combination Angiostatin and Endostatin Gene Transfer Induces Synergistic Antiangiogenic Activity in Vitro and Antitumor Efficacy in Leukemia and Solit Tumor in Mice. Department of Molecular Pharmacology and Department of
Medicine Stanford University Medical Center. Stanford. Sweden. 2001. Vol 3. No 2.
38. Gately S, Twardowski P, Stack MS, et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Department of Obstetrics and Gynecology Northwestern University School of Medicine. Chicago. 1997. Medical Sciences. Vol. 94, pp. 10868-10872.
39. Schorge, Schaffer, Halvorson, et al. Epithelial Ovarian Cancer. Gynecologic Oncology. Williams Gynecology. The McGraw-Hill Compenies.2008:716-736
40. Nyberg Pia, Xie L, Kalluri R. Endogenous Inhibitors of Angiogenesis. Department of Medicine Beth Israel Deaconess Medical Center and Harvard Medical School. Boston. Massachusetts. 2005. ;65:3967-3979.
41. Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Department of Anatomical Pathology, Canterbury Health, Christchurch. New Zealand. Vol 2. 2001. 278-89. 42. Jurasz Paul, Alonso D, Blanco SC, Murad F, Radomski MW.
Generation and role of angiostatin in human platelets. The American Society of Hematology. Department of Pharmacology University of Alberta Edmonton. Canada. 2003. Vol 102, Number 9; 3217-3223
43. Wilczynska U, Kucharska A, Szary J, Szala S. Combined delivery of an antiangiogenic protein (angiostatin) and an immunomodulatory gene(interleukin-12)in the treatment of murine cancer. Department of Molecular Biology. Center of Oncology-Maria Sklodowska-Curie Memorial Institute. Gliwice. Poland. Vol 8. No 4. 2001; 1077-1084. 44. Lucas R, Holmgren L, B Garcia, et al. Blood Multiple Forms of
Angiostatin Induce Apoptosis in Endothelial Cells. The American Society of Hematology. Department of Anasthesiology, pharmacology, and Surgycal Intensive Care, and Department of Internal Medicine. Geneva University Hospital. Geneva. Switzerland. Vol. 92, no 12. 1998: pp 730-4741.
45. Hong Yang, Yin Wu, Tonghui MA, Baiqu Huang. Progress in studies of angiostatin and its anti-tumor effects. Institute of Genetics and Cytology, Northeast Normal University. Changchun. China. Chinese Science Bulletin. Vol. 46. No 6. 2001. 456-460.
46. Wu Tianfu, Du Yong, Han Jie, et all. Urinary Angiostatin-a novel marker of renal pathology chronicity in lupus nephritis. Department of Pathology Baylor University Medical Center at Dallas. The American Society for Biochemistry and Molecular Biology. 2013. 3-31.
47. Moser TL, Stack MS, Asplin, et al. Angiostatin bonds ATP synthase on the surface of human endothelial cells. Department of Molecular Biology Odense University. Denmark. 1999. Vol. 96, pp 2811-2816.
48. Park Kyoungsoo, Lim DL, Don PS, Young KM, et al. Angiogenesis Inhibitor Derived from Angiostatin Active Sites. Department of Chemistry and Bio/Molecular Informatics Center. Konkuk University Seoul. Korea. 2004. Vol. 25, no. 9. 1331-1335
49. Alvarez AA, Krigman HR, Whitaker RS, et al. The Prognostic Significance of Angiogenesis in Epithelial Ovarian Carcinoma. Departments of Obstetrics and Gynecology and Pathology. Division of Gynecology Onkology. Duke University Medical Center. Durham. North Carolina. 1999. Vol 5. 587-591
50. O’Reilly M, Wiederschain D, Stetler-Stevenson WG, Folkman Judah, Moses MA. Regulation of Angiostatin Production by Matrix Metalloproteinase-2 in a Model of Concomitant Resistance. Department surgery and Department of Cell Biology Harvard Medical School Boston. Massachusetts. Vol 274. No 41. 1999,pp. 29568-29571.
51. Mu Wei, Long DA, Ouyang X, Agarwal A, et al. Angiostatin overexpression is associated with an improvement in chronic kidney injury by an anti-inflammatory mechanism. Division of Nephrology and Departments of Ophthamology Molecular Genetics and Microbiology University oh Florida. Gainesville. Florida. Am J Physiol Renal Physiol 296. 2009: F145-F152.
52. O’Reilly M, Holmgren L, Shing Y, et al. Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases
by a Lewis Lung Carcinoma. Department of Biological Structure University of Washington Seattle. Washington. 1994. Vol.79. 325-328. 53. Cao Y. Richard JW. Davidson D. Schaller J. Et al. Kringle Domains of
Human Angiostatin Characterization of the anti-proliferative activity on endothelial cells. Department of Chemistry. University of Notre Dame. South Bend. Indiana. 996. Vol. 271. No 46, pp. 29461-29467.
54. Polanski Malu and Anderson N. Leigh. A List of Candidate Cancer Biomarkers for Targeted Proteomics. The Plasma Proteome Institute. Washington. USA. 2006: 2. 1-48.
55. Hardiman A, Noviani R, dkk. Kebijakan dan Pokok – pokok Kegiatan Pengendalian Penyakit Kanker di Indonesia. Rumah Sakit Kanker Darmais. Indonesia Journal of Cancer. Volume 1, No 2.Jakarta. April – Juni 2007
56. Berek JS, Epithelial Ovarian Cancer. Practical Gynecologic Oncology, fourth edition, Lippincott Williams & Wilkins, Philadelphia.2005: 443-510
57. Aman RA. Gondhowiardjo S. Rachman A. et al. Basic science of oncology ilmu onkologi dasar. Perhimpunan onkologi Indonesia. Fakultas Kedokteran Universitas Indonesia. Jakarta. 2010
58. Kresno Siti Boedina. Ilmu Dasar Onkologi. Angiogenesis. Fakultas Kedokteran Universitas Indonesia. Edisi ketiga. Jakarta. 2012. 344-362.
59. Huey CY. Lin wH. Kwan CC. et al. Angiostatin antagonizes the action of VEGF-A in human endothelial cell via two distinct pathways. Institute of Basic Medical Sciences. National Cheng Kung University Medical College. Tainan. Taiwan. 2003. 804-810.
60. Balicka AR. Ramer C. De la Rosa CM.et al. Angiostatin inhibits endothelial MMP-2 and MMP-14 expression: A hypoxia specific mechanism of action.
61. Sopiyudin M, Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan, edisi 3, Penerbit Salemba Medika, 2010: 81-90.
62. Ali. Sensitivitas & Spesifisitas Human Epididymis Protein-4 (HE) Dan Antigen Kanker CA125 Sebagai Biomarker pada Tumor Ovarium Jinak dan Ganas di RSUP. H. Adam Malik Medan. Dept. Obstetri dan Ginekologi FK. USU. Medan. 2012.
63. Pizzo Sw. Moser Tl. Stack Ms et al. The Mechanism of action of Angiostatin can you teach an old dog new tricks? Thromb Haemost 2002; 87: 394-401